COMMUNIQUÉS West-GlobeNewswire
-
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
21/05/2026 -
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
21/05/2026 -
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
21/05/2026 -
Vitacore Announces World-First Custom-Fit CPAP Mask Following Health Canada MDL Approval
21/05/2026 -
SlimTide Examined: 2026 Consumer-Focused Analysis of Ingredients, Claims, and Label Transparency
21/05/2026 -
Biodesix to Participate in Upcoming Investor Conferences
21/05/2026 -
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
21/05/2026 -
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
21/05/2026 -
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
21/05/2026 -
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21/05/2026 -
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
21/05/2026 -
Hemab Therapeutics Reports First Quarter 2026 Financial Results
21/05/2026 -
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
21/05/2026 -
Zen Leaf Dispensaries Mark 10-Year Las Vegas Anniversary with “All-in-at-10” Community-Focused Celebrations May 21st-May 30th
21/05/2026 -
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026 -
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
21/05/2026 -
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026 -
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
21/05/2026 -
Picard Medical / SynCardia Reports First Quarter 2026 Financial Results
21/05/2026
Pages